Kite Pharma, Inc.

A system for sealing a tube extending from a product bag used in cryogenic freezing includes a support having a top surface; a bag guide secured to the support so as to upstand from the top surface, the bag guide including a boundary face; and a tube sealer at least partially upstanding from the top surface of the support, the tube sealer including a first sealing head and a second sealing head and being movable between an open position and a closed position. A spacer arm is movable between a blocking position wherein the spacer arm is disposed between the bag guide and the tube sealer so that the spacer arm at least partially covers the boundary face and an unblocking position wherein the boundary face is openly exposed.

The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.

Provided herein are compositions and methods for fluorescence activated cell analysis of white blood cell populations. The compositions and methods enable thorough characterization each subpopulation of a greater cell population of leukocytes. Additionally, the biomarker-based standards and methods of are expedited as compared to the conventional technology and produce a positive control test material that reduces the cost, expedites the process, and improves the outcome of fluorescence activated cell analysis of blood cell populations.

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

Provided herein are methods for measuring antigen recognition response by lymphocytes upon exposure to a target antigen. Methods are disclosed for functionalizing red blood cells with antigens recognized by lymphocytes. By contacting antigen functionalized red blood cells with lymphocytes having specificity for the antigen, lymphocyte recognition response can be measured. The recognition response can be in the form of cytokine release by the lymphocytes and/or the expression of activation and/or differentiation markers on the surface of the lymphocytes.

The present disclosure provides DNA molecules, such as transfer plasmids, useful for manufacturing packaged retroviral vectors encoding a therapeutic protein such as chimeric antigen receptors (CARs) and T cell receptors (TCRs). The encoded retroviral transcript in the DNA molecule includes a transgene, an elongation factor 1-alpha 1 (EF1α) promoter, without the EF1α intron, operably linked to the transgene and a Rev response element (RRE).

Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy.

The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of improvement of cytokine signaling.

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.